Navigation Links
3.0xx SheerVision Ultra-Light TTL Loupes - Titanium Frame

Products3.0xx SheerVision Ultra-Light TTL Loupes - Titanium Frame
Company SheerVision
Item 3.0xx SheerVision Ultra-Light TTL Loupes - Titanium Frame
Features 
  • Sharp, edge-to-edge clarity
  • High resolution optics
  • Lightweight design
  • Multi-coated for: anti-glare, anti-fog and scratch-resistance
  • Manufacturer direct pricing - save up to 40% off the competition
  • 30 day trial period
  • 100% satisfaction guaranteed
Description Experience the finest surgical-quality loupes available at manufacturer-direct prices. We set the standard for innovative optical design, combining superior quality withunmatched customer support. Delivering optimum performance with maximum comfort, SheerVision loupes are the clear choice for medical professionals worldwide. All SheerVision loupes come compete with clear lens covers, fully-lined case, side shields, safety strap, flip-up paddle and a lens cleaning cloth.
Info SheerVision
Customer Service: (877) 678-4274

Related medicine products :

1. 3.0xx SheerVision Ultra-Light TTL Loupes - SV Sport Frame
2. 3.0xx SheerVision Ultra-Light Loupes - SV Sport Frame
3. 3.0xx SheerVision Ultra-Light Loupes - Titanium Frame
4. SheerVision Surgical Magnifying Loupes
5. SheerVision FireFly LED Light System
6. FireFly LED Light System & SheerVision 2.5x Titanium-Frame Loupe Package
7. 2.5xx SheerVision Ultra-Light Loupes - SV Sport Frame
8. 3.0x SheerVision Loupes - Titanium Frame
9. 3.0x SheerVision Loupes - SV Sport Frame
10. 3.5x SheerVision Loupes - SV Sport Frame
11. 3.5x SheerVision Loupes - Titanium Frame
Breaking Medicine Technology:Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 2New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 3New Analytical Training Lab Standardizes on Waters Innovative Technologies to Achieve Educational Goals 4Humans damaging the oceans 9411 1Humans damaging the oceans 9411 2Humans damaging the oceans 9411 3Bizarre walking bat has ancient heritage 9408 1Bizarre walking bat has ancient heritage 9408 2Organic food not nutritionally better than conventionally produced food 9405 1Organic food not nutritionally better than conventionally produced food 9405 2